There were significant increases from baseline to follow-up in the outdoor gym area for: MVPA (6 to 40%; p<0.001); and seniors' use (1.4 to 6%; p<0.001).
Similarly, compared to the early-season group, athletes injured in the late-season period reported almost twice as many individual symptom increases from baseline following SRC.
LS mean scores for all domains and both PCS and MCS showed statistically significant increases from baseline to final acute phase visit (all P < 0.001).
Analysis of covariance (ANCOVA) investigated differences across season period groups for: (1) neurocognitive test scores, (2) total symptom scores (TSS), and (3) individual symptom increases from baseline within 1-week post-injury.
Additionally, a chi-squared test was performed as a means to test individual symptom increases from baseline based on a previously validated cutoff score (2+ symptoms, increased 1+ point) [45].
Mean increases from baseline to day 2 were 22.93 msec and 14.65 msec, respectively.
For example, in the subpopulation of memory cells recorded from the parietal cortex, 90.1% of the cells exhibited increases from baseline to delay of less than 10 Hz, and 69.9% of frequency changes were less than 5 Hz.
Of note, all of the genes encoding hypothetical proteins associated with in vitro biofilm production showed expression levels that were increased by two-fold or more in vivo, ranging from 4.4 to 24.8 fold increases from baseline (Table 2).
In comparison, a meta-analysis showed the average increases from baseline in the IL-2 and ART-treated groups in the three other trials was +417 compared to +77 cells/mm3 in the ART alone groups [23], [24].
In the active treatment group compliant subjects were defined as those who responded with increases from baseline to follow-up in plasma folate of >10 nmol/L and in vitamin B12 of >150 pmol/L.
Increases from baseline were also observed for tiotropium (11.32%).
